Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple alert get more ER patients with opioid addiction the right medication?

NCT ID NCT07793383

Disease control Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

Researchers at Yale are testing a decision-support tool called EMBED CDS that alerts emergency department doctors when a patient with opioid use disorder might be eligible for buprenorphine, a medication that eases withdrawal and cravings. The study involves 100 adults with moderate to severe opioid use disorder who visit the ER. The goal is to see if the tool increases the number of patients who start buprenorphine in the emergency department or get a prescription when they leave.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A clinical decision-support tool (EMBED CDS) that alerts emergency department doctors when a patient with opioid use disorder may be eligible for buprenorphine treatment.
What this could lead to
If it works, this tool could help more emergency room patients with opioid use disorder start buprenorphine, a medication that reduces cravings and withdrawal, potentially improving recovery outcomes.
What could go wrong
This is an early-stage usability test with 100 participants, so it may not show a clear benefit. The tool's effect on real-world care and long-term outcomes remains uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Emergency department patient * 18 years of age or older * Moderate to severe opioid use disorder Exclusion Criteria: * Under 18 years of age * Pregnant * Currently receiving medication for opioid use disorder

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clinical decision support are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence opioid abuse

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clinical decision support Opioid abuse (disorder)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Yale New Haven Hospital

    New Haven, Connecticut, 06520, United States

  • Yale New Haven Hospital- St. Raphael

    New Haven, Connecticut, 06510, United States

  • Yale New Haven Shoreline Medical Center

    Guilford, Connecticut, 06437, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.